Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Bruce J KinonJohn M Kane

Abstract

Our objective was to prospectively assess whether early (ie, 2 weeks) response to an antipsychotic predicts later (12-week) response and whether 'switching' early non-responders to another antipsychotic is a better strategy than 'staying'. This randomized, double-blind, flexible-dosed, 12-week study enrolled 628 patients diagnosed with schizophrenia or schizoaffective disorder. All initiated treatment with risperidone. Early response was defined as > or =20% improvement on the Positive and Negative Syndrome Scale (PANSS) total score following 2 weeks of treatment. Early responders (ERs) continued on risperidone, whereas early non-responders (ENRs) were randomized (1 : 1) to continue on risperidone 2-6 mg/day or switch to olanzapine 10-20 mg/day for 10 additional weeks. Compared with ENRs, risperidone ERs showed significantly greater reduction in PANSS total score (end point; p<001). Early response/non-response was highly predictive of subsequent clinical outcomes. Switching risperidone ENRs to olanzapine at week 2 resulted in a small but significantly greater reduction in PANSS total score (end point; p=0.020) and in depressive symptoms (end point; p=0.004); the reduction in PANSS was greater among those who were still moderate...Continue Reading

References

Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Jun 11, 2003·Archives of General Psychiatry·John M DavisIra D Glick
Nov 5, 2003·The American Journal of Psychiatry·Christoph U CorrellJohn M Kane
Dec 10, 2003·Archives of General Psychiatry·Ofer AgidRobert B Zipursky
Jun 29, 2005·Schizophrenia Research·Stefan LeuchtRolf R Engel
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Jun 9, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Hitoshi TakahashiHisashi Higuchi
Dec 2, 2006·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Josep Maria HaroUNKNOWN SOHO Study Group
Dec 8, 2006·The American Journal of Psychiatry·Susan M EssockJeffrey A Lieberman
Mar 29, 2007·The Journal of Clinical Psychiatry·Stefan LeuchtJohn M Kane
Apr 10, 2008·Current Medical Research and Opinion·Douglas E FariesBruce J Kinon
May 27, 2008·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Peter Falkai
Jun 7, 2008·Schizophrenia Research·Jonathan M MeyerJeffrey A Lieberman
Jun 24, 2008·Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists·Deanna L KellyRobert P McMahon
Nov 7, 2008·Biological Psychiatry·W Wolfgang FleischhackerWilliam H Carson
Nov 11, 2008·Schizophrenia Research·Robert A RosenheckJeffrey Lieberman

❮ Previous
Next ❯

Citations

Sep 22, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Ion-George AnghelescuMark E Schmidt
Oct 12, 2010·Psychological Medicine·M CaseB J Kinon
Sep 22, 2011·ClinicoEconomics and Outcomes Research : CEOR·Xiaomei PengJohn M Kane
Sep 24, 2011·The Journal of Clinical Psychiatry·Juan A GallegoJohn M Kane
Oct 7, 2010·The Journal of Clinical Psychiatry·John M Kane, Christoph U Correll
Sep 14, 2014·Asian Journal of Psychiatry·Dawn BruijnzeelRajiv Tandon
Jul 20, 2011·BMC Psychiatry·Michael ObermeierFlorian Seemüller
Dec 22, 2011·The British Journal of Psychiatry : the Journal of Mental Science·Takefumi SuzukiDavid C Mamo
Nov 8, 2012·Journal of Clinical Psychopharmacology·Ching-Hua LinHsien-Yuan Lane
Jun 27, 2013·Journal of the American Academy of Child and Adolescent Psychiatry·Christoph U CorrellRaymond Mankoski
Dec 20, 2011·Clinical Therapeutics·Christoph U CorrellJohn M Kane
Jan 25, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Rebecca Schennach-WolffMichael Riedel
Jun 4, 2015·Psychiatry and Clinical Neurosciences·Kotaro Hatta
Mar 12, 2015·Human Psychopharmacology·Bonginkosi ChilizaRobin Emsley
May 17, 2011·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Michael RiedelRebecca Schennach-Wolff
Aug 1, 2015·European Archives of Psychiatry and Clinical Neuroscience·Stephan HeresStefan Leucht
Feb 26, 2015·Clinical Schizophrenia & Related Psychoses·Bruno Bertolucci OrtizRodrigo Affonseca Bressan
Jul 27, 2010·Schizophrenia Research·Rajiv TandonMatcheri S Keshavan
Jun 5, 2012·Schizophrenia Research·Rebecca SchennachMichael Riedel
Feb 23, 2013·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Rebecca SchennachHans-Jürgen Möller
May 23, 2014·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Kotaro Hatta, Hiroto Ito

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here